New Drug Treats Rare Blood Clotting Disorder

Caplacizumab-yhdp (Cablivi) is the first drug specifically indicated for acquired thrombotic thrombocytopenic purpura, a rare and potentially life-threatening blood clotting disorder. It is prescribed in combination with plasmapheresis and immunosuppressive therapy.The drug carries a warning that severe bleeding can occur with use, although the most common adverse effects are headache and minor bleeding from the nose or gums.Caplacizumab-yhdp is given initially as an iv bolus and then as a subcutaneous injection along with plasmapheresis.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research